<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665050</url>
  </required_header>
  <id_info>
    <org_study_id>pPCV-002</org_study_id>
    <secondary_id>pPCV-002</secondary_id>
    <secondary_id>jRCT2071200094</secondary_id>
    <nct_id>NCT04665050</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Japanese Adults (pPCV-002)</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 1, randomized, double-blind, active-comparator-controlled study is&#xD;
      to compare the safety, tolerability, and immunogenicity of a polyvalent pneumococcal&#xD;
      conjugate vaccine (pPCV) with that of PNEUMOVAX™ in healthy Japanese adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Actual">April 6, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</measure>
    <time_frame>Up to 5 days postvaccination</time_frame>
    <description>Solicited injection-site AEs include tenderness/pain, redness/erythema, and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Systemic AE</measure>
    <time_frame>Up to 5 days postvaccination</time_frame>
    <description>Solicited systemic AEs include headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 30 days postvaccination</time_frame>
    <description>A vaccine-related SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in pPCV and Pneumovax™23</measure>
    <time_frame>Day 30 postvaccination</time_frame>
    <description>The GMTs for serotypes common to pPCV and PNEOMOVAX™23 will be determined using the muliplex opsonophagocytic assay (MOPA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in pPCV and Pneumovax™23</measure>
    <time_frame>Day 30 postvaccination</time_frame>
    <description>The GMCs for serotype-specific pneumococcal IgG antibodies will be determined using pneumococcal electrochemiluminescence (PnECL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific OPA GMTs for the Unique Serotypes in pPCV</measure>
    <time_frame>Day 30 postvaccination</time_frame>
    <description>The GMTs for serotypes unique to pPCV will be determined using the MOPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific IgG GMCs for the Unique Serotypes in pPCV</measure>
    <time_frame>Day 30 postvaccination</time_frame>
    <description>The GMCs for serotype-specific pneumococcal IgG antibodies unique to pPCV will be determined using PnECL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) from Baseline in Serotype-specific OPA GMTs for the Common Serotypes in pPCV and Pneumovax™23</measure>
    <time_frame>Baseline (Day 1) and Day 30 postvaccination</time_frame>
    <description>The GMFR in GMTs from baseline to Day 30 of serotypes common to pPCV and PNEOMOVAX™23 will be determined using the MOPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR from Baseline in Serotype-specific IgG GMCs for the Common Serotypes in pPCV and Pneumovax™23</measure>
    <time_frame>Baseline (Day 1) and Day 30 postvaccination</time_frame>
    <description>The GMFR in GMCs from baseline to Day 30 of serotype-specific pneumococcal IgG antibodies will be determined using PnECL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>pPCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of pPCV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNEUMOVAX™23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a single dose of PNEUMOVAX™23 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pPCV</intervention_name>
    <description>pPCV vaccine 1.0 mL solution, at a dose to be determined, for intramuscular (IM) injection.</description>
    <arm_group_label>pPCV</arm_group_label>
    <other_name>Polyvalent pneumococcal conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>PNEUMOVAX™23 0.5 mL solution, at a dose to be determined, for IM injection.</description>
    <arm_group_label>PNEUMOVAX™23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  is a healthy Japanese male or female ≥20 years of age at time of randomization&#xD;
&#xD;
          -  male participants must agree to be abstinent or use contraception during the study and&#xD;
             for ≥30 days after completing the study&#xD;
&#xD;
          -  female participants must not be pregnant or breastfeeding, and is either:&#xD;
&#xD;
          -  not a woman of childbearing potential (WOCBP) or&#xD;
&#xD;
          -  a WOCBP who agrees to remain abstinent or use contraception during the study and for&#xD;
             ≥30 days after completing the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1&#xD;
&#xD;
          -  has a known hypersensitivity to any vaccine components&#xD;
&#xD;
          -  has impaired immunological function&#xD;
&#xD;
          -  has a coagulation disorder&#xD;
&#xD;
          -  had a recent febrile illness (axillary temperature ≥37.5°C or equivalent) within 72&#xD;
             hours before Day 1&#xD;
&#xD;
          -  has a known malignancy that is progressing/requiring treatment&#xD;
&#xD;
          -  has received, or is expected to receive, a pneumococcal vaccine outside the study&#xD;
             protocol&#xD;
&#xD;
          -  has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14&#xD;
             consecutive days and has not completed the regimen for ≥30 days prior to Day 1&#xD;
&#xD;
          -  is receiving immunosuppressive therapy&#xD;
&#xD;
          -  has received any non-live vaccine from 14 days prior to Day 1 other than inactivated&#xD;
             influenza vaccine&#xD;
&#xD;
          -  has received any live vaccine from 30 days prior to Day 1&#xD;
&#xD;
          -  has received a blood transfusion or blood products&#xD;
&#xD;
          -  has participated in another clinical trial within 2 months of this study&#xD;
&#xD;
          -  has clinically relevant drug or alcohol abuse&#xD;
&#xD;
          -  has any condition that, in the opinion of the investigator, precludes participation in&#xD;
             this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Souseikai PS Clinic ( Site 0201)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souseikai Nishikumamoto Hospital ( Site 0202)</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4157</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

